Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study

被引：0
|
作者：
Brown, Robert S., Jr. [1 ]
Hezode, Christophe [2 ]
Wang, Stanley [3 ]
Buti, Maria [4 ,5 ]
Chuang, Wan-Long [6 ,7 ]
Aguilar, Humberto I. [8 ]
Horvath, Gabor [9 ]
Rosado-Carrion, Barbara [10 ]
Rodriguez-Perez, Federico [11 ,12 ]
Cohen, Eric [3 ]
Hui, Yiran B. [3 ]
Schnell, Gretja [3 ]
Lin, Chih-Wei [3 ]
Rodrigues, Lino, Jr. [3 ]
Trinh, Roger [3 ]
Mensa, Federico J. [3 ]
Felizarta, Franco
机构：
[1] New York Presbyterian Hosp, Cornell Med Coll, Dept Med, Ctr Liver Desease & Transplantat, Nyc, NY USA
[2] Univ Paris Est, Hop Henri Mondor, Dept Hepatol, Paris, France
[3] Abbvie Inc, N Chicago, IL USA
[4] Hosp Univ Vall dHebron, Barcelona, Spain
[5] Vall DHebron Univ Hosp, Liver Unit, Barcelona, Spain
[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatitis Ctr, Kaohsiung, Taiwan
[8] Louisiana Res Ctr, Shreveport, LA USA
[9] Hepatol Ctr Buda, Budapest, Hungary
[10] Ghgcpr Res Inst, Ponce, PR USA
[11] Ghwc, San Juan, PR USA
[12] Gastroenterol Sect, San Juan, PR USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
715A
引用
收藏
页码：425A / 426A
页数：2
相关论文
共 50 条
  • [41] SAFETY AND EFFECTIVENESS USING 8 WEEKS OF GLECAPREVIR/PIBRENTASVIR IN HCV-INFECTED TREATMENT-NAIVE PATIENTS WITH COMPENSATED CIRRHOSIS: THE CREST STUDY
    Cornberg, Markus
    Ahumada Jimenez, Adriana Maria
    Aghemo, Alessio
    Andreoni, Massimo
    Bhagat, Abhi
    Butrymowicz, Isabel
    Carmiel, Michal
    Chodick, Gabriel
    Conway, Brian
    Fang, Yixin
    Gasbarrini, Antonio
    Hueppe, Dietrich
    Jorquera, Francisco
    Lampertico, Pietro
    Manzano Alonso, Maria Luisa
    Myles, Lindsay
    Persico, Marcello
    Ramji, Alnoor
    Sarrazin, Christoph
    Villa, Erica
    Weil, Clara
    Uriz Otano, Juan Isidro
    HEPATOLOGY, 2021, 74 : 575A - 576A
  • [42] Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)
    Hassanein, Tarek I.
    Wyles, David L.
    Wang, Stanley
    Kwo, Paul Y.
    Shiffman, Mitchell L.
    Younes, Ziad
    Greenbloom, Susan
    Stedman, Catherine A.
    Sasadeusz, Joe
    Aguilar, Humberto I.
    Heo, Jeong
    Liu, Ran
    Ng, Teresa
    Lin, Chih-Wei
    Mensa, Federico J.
    HEPATOLOGY, 2016, 64 (06) : 1128A - 1128A
  • [43] Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naive Patients with Compensated Cirrhosis: The CREST Study
    Cornberg, Markus
    Ahumada, Adriana
    Aghemo, Alessio
    Andreoni, Massimo
    Bhagat, Abhi
    Butrymowicz, Isabel
    Carmiel, Michal
    Chodick, Gabriel
    Conway, Brian
    Song, Yanna
    Gasbarrini, Antonio
    Huppe, Dietrich
    Plaza, Francisco Jorquera
    Lampertico, Pietro
    Alonso, Maria Luisa Manzano
    Myles, Lindsay
    Persico, Marcello
    Ramji, Alnoor
    Sarrazin, Christoph
    Villa, Erica
    Weil, Clara
    Otano, Juan Isidro Uriz
    ADVANCES IN THERAPY, 2022, 39 (07) : 3146 - 3158
  • [44] Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
    Pietro Lampertico
    Stefan Mauss
    Marcello Persico
    Stephen T. Barclay
    Steven Marx
    Kristina Lohmann
    Mark Bondin
    ZhenZhen Zhang
    Fiona Marra
    Pamela S. Belperio
    Heiner Wedemeyer
    Steven Flamm
    Advances in Therapy, 2020, 37 : 4755 - 4756
  • [45] Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
    Huff, Jamie
    Andersen, Rebecca
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (03) : 262 - 276
  • [46] Efficacy and Safety of 8-Weeks of Glecaprevir/Pibrentasvir in Treatment-Naive Adults with HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
    Fontana, Robert J.
    Lens, Sabela
    McPherson, Stuart
    Elkhashab, Magdy
    Katzarov, Krum
    Pires, Ana Gabriela
    Xue, Zhenyi
    Trinh, Roger
    Rodrigues, Lino, Jr.
    Porcalla, Ariel
    Zeuzem, Stefan
    HEPATOLOGY, 2018, 68 : 388A - 389A
  • [47] Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
    Yang, Chun-Chi
    Huang, Chung-Feng
    Chang, Te-Sheng
    Lo, Ching-Chu
    Hung, Chao-Hung
    Huang, Chien-Wei
    Chong, Lee-Won
    Cheng, Pin-Nan
    Yeh, Ming-Lun
    Peng, Cheng-Yuan
    Cheng, Chien-Yu
    Huang, Jee-Fu
    Bair, Ming-Jong
    Lin, Chih-Lang
    Yang, Chi-Chieh
    Wang, Szu-Jen
    Hsieh, Tsai-Yuan
    Lee, Tzong-Hsi
    Lee, Pei-Lun
    Wu, Wen-Chih
    Lin, Chih-Lin
    Su, Wei-Wen
    Yang, Sheng-Shun
    Wang, Chia-Chi
    Hu, Jui-Ting
    Mo, Lein-Ray
    Chen, Chun-Ting
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Huang, Chia-Sheng
    Chen, Guei-Ying
    Kao, Chien-Neng
    Tai, Chi-Ming
    Liu, Chun-Jen
    Lee, Mei-Hsuan
    Kuo, Hsing-Tao
    Tsai, Pei-Chien
    Dai, Chia-Yen
    Kao, Jia-Horng
    Lin, Han-Chieh
    Chuang, Wang-Long
    Tseng, Kuo-Chih
    Chen, Chi-Yi
    Yu, Ming-Lung
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1199 - 1213
  • [48] Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
    Markus Cornberg
    Adriana Ahumada
    Alessio Aghemo
    Massimo Andreoni
    Abhi Bhagat
    Isabel Butrymowicz
    Michal Carmiel
    Gabriel Chodick
    Brian Conway
    Yanna Song
    Antonio Gasbarrini
    Dietrich Hüppe
    Francisco Jorquera Plaza
    Pietro Lampertico
    Maria Luisa Manzano Alonso
    Lindsay Myles
    Marcello Persico
    Alnoor Ramji
    Christoph Sarrazin
    Erica Villa
    Clara Weil
    Juan Isidro Uriz Otano
    Advances in Therapy, 2022, 39 : 3146 - 3158
  • [49] Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
    Asselah, Tarik
    Kowdley, Kris V.
    Zadeikis, Neddie
    Wang, Stanley
    Hassanein, Tarek
    Horsmans, Yves
    Colombo, Massimo
    Calinas, Filipe
    Aguilar, Humberto
    de Ledinghen, Victor
    Mantry, Parvez S.
    Hezode, Christophe
    Marinho, Rui Tato
    Agarwal, Kosh
    Nevens, Frederik
    Elkhashab, Magdy
    Kort, Jens
    Liu, Ran
    Ng, Teresa I.
    Krishnan, Preethi
    Lin, Chih-Wei
    Mensa, Federico J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) : 417 - 426
  • [50] Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study
    Fiore, Vito
    Ranieri, Roberto
    Dell'Isola, Serena
    Pontali, Emanuele
    Barbarini, Giorgio
    Prestileo, Tullio
    Marri, Daniele
    Starnini, Giulio
    Sotgiu, Giovanni
    Madeddu, Giordano
    Babudieri, Sergio
    LIVER INTERNATIONAL, 2021, 41 (02) : 271 - 275
12345